Areteia Therapeutics – AR-DEX-22-02 – Dexpramipexole

Do you or your child experience uncontrolled severe eosinophilic asthma?


  • This study is looking to see whether Dexpramipexole will reduce inflammation and swelling within the respiratory system thereby reducing asthma symptoms.
  • Study drug has already been shown to lower the absolute Eosinophil Count (AEC) and increase forced expiratory volume (FEV). High AEC is associated with increased inflammation and swelling within respiratory system.
ASHMA poto 01.jpg

The Study

  • A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

Study Benefits

  • Compensation for time and travel
  • Potential improvement of Asthma symptoms

Study Participant Criteria

  • Male or females
  • 12 years of age and older
  • Diagnosed with asthma for at least one full year
  • Documented history of AT LEAST TWO asthma exacerbations requiring treatment with systemic corticosteroids in the past twelve months prior to screening
  • CAN NOT be a smoker in the last year
  • CAN NOT have been treated with a biologic in the last 5 months

Study Participant Expectations

  • 52-week treatment period with weekly clinic visits
  • 8 in-person visits and one phone visit
  • Twice Daily oral medication
  • 8 blood draws throughout the study

“Did You Know”

  • It is estimated that approximately 10% of patients diagnosed with asthma are categorized as severe, and within that patient population half of them experience eosinophilic asthma.